Patients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteria
Patients with INRG stage L tumors without amplification of MYCN regardless of tumor histology (may meet criteria for may meet criteria for high risk classification but are not eligible for this trial)
Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest may be eligible provided they meet all other inclusion/exclusion criteria
Pathologic criteria:
Patients crossing over from monotherapy to combination therapy do not have to be fully rescreened; however, they do need to meet performance status, organ function, and blood parameters and not meet any of the exclusion criteria
Patients screened for this trial should be expected to meet the criteria for treatment
Subjects with treated brain metastases are eligible provided they meet the following criteria:
Grade I meningiomas will be allowed as long as they meet criteria for progression
Patients who progressed after initial therapy\r\n* Subjects whose therapy changed due to suboptimal response, intolerance, etc., remain eligible, provided they do not meet criteria for progression\r\n* No more than two regimens will be allowed excluding dexamethasone alone
To be eligible for participation in the study, patients must meet all of the following inclusion criteria:
Blood counts performed within  days prior to randomization must meet the following criteria:
Patients with brain metastases unless they meet the criteria
Patients must meet ONE of the criteria outlined in either a, b, c OR d:
Each patient must meet the following criteria:
Patients must not meet any of the following criteria:
Patients who do not meet inclusion criteria
NOTE: Patients are expected to initiate therapy as close to day + as possible; no patient may initiate therapy before day + and initiation of therapy beyond day + is allowed ONLY for patients who meet all eligibility criteria except for hematologic parameters, in which case patients may be delayed until their hematologic laboratories meet criteria but no later than day +; regardless of the time of therapy initiation, patients must meet all eligibility criteria and must have completed all consent documentation and screening procedures within the specified window
DONOR: Failure to meet institutional criteria for stem cell donation
Patient has a WHO performance status -. Patients in Arm  to  must also meet the following inclusion criteria:
Study subjects <  years of age who cannot undergo the leukapheresis procedure, do not meet the disease staging and/or the size criteria for frequent blood donations
Meet standard criteria for RIT:\r\n* < % marrow involvement with FL\r\n* No evidence of myelodysplasia
Patients who have had brain metastases unless they meet the criteria.
Failure to meet any of the criteria set forth in the inclusion criteria section
Meet the following disease activity criteria:
Pregnant patients do not meet inclusion criteria for radiation therapy.\r\n* Patients who subsequently become pregnant may continue follow up within the protocol, but a negative urine pregnancy test will need to be obtained before additional lesions may be enrolled.
All patients must meet the following inclusion and exclusion criteria; NO EXCEPTIONS WILL BE GIVEN
Subjects who fail to meet the above criteria
Patients must meet eligibility in at least  of the following  groups:
LYMPHODEPLETION: Subjects must have autologous transduced activated T-cells that meet the certificate of analysis (CofA) acceptance criteria
Subjects must meet all of the following criteria to be included in this study:
Subjects who meet any of the following criteria will be excluded from this study:
Persons who do not meet the age and organ function criteria specified above
Each patient must be positive for HLA-A* and meet all of the following inclusion criteria to be enrolled in the study
Patients must have baseline evaluations performed prior to the first dose of study drug and must meet all inclusion and exclusion criteria
Must meet one or more of the consensus criteria for initiating treatment MM Participants:
Must meet eligibility criteria for initiation of part A with the exception of being allowed to have prior nivolumab in part A of this protocol
Lysate must meet release criteria
Subject for whom tumor lysate does not meet release criteria
Patients are required to meet the following criteria to proceed to AHSCT:
Osteosarcoma participants receiving combination therapy of lenvatinib with ifosfamide and etoposide should meet only Inclusion Criteria Numbers  through  (after progression in Cohort B).
Osteosarcoma participants receiving combination therapy of lenvatinib with ifosfamide and etoposide should meet all the exclusion criteria, with the exception of Criterion Number .
Patients are required to meet criteria for initiation of therapy for their B-NHL according to published guidelines by the National Comprehensive Cancer Network (NCCN)
Meet criteria for a current major depressive episode or suicidality
Patients must meet the following clinical criteria to receive CMVpp-CTL infusions
Patient does not meet the requirements for prior ipilimumab treatment listed in inclusion above
Patients must meet IWCLL  Guideline [] criteria for active disease requiring treatment. Each patient with NHL must meet all of the following inclusion criteria to be enrolled on the study:
Patients must have relapsed or refractory disease after at least one prior therapy and not have traditional options available or decline these. All patients must meet all of the following inclusion criteria to be enrolled on the study:
Note: patients enrolled after chemotherapy do not have to meet the above criteria
Blood counts performed within  weeks prior to study entry must meet the following criteria:
Failure to meet inclusion criteria;
Must meet following requirements:
patients with CRPC must meet PCWG criteria for disease progression at trial entry
Female patients are eligible for the study if they meet the following criteria:
Patients with an active or uncontrolled infection; patients on prolonged antifungal therapy are still eligible if they are culture and biopsy negative in suspected radiographic lesions and meet other organ function criteria
MAINTENANCE CRITERIA:
DONOR: Failure to meet institutional criteria for donation as described in the Standard Practice Guidelines
Patients with prior progressive disease who do not meet criteria above, are eligible as long as they have not been off treatment for >  months prior to enrollment on NANT -
Any of the dosimetric treatment criteria as defined have not been met; patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as defined in this protocol and will come off the study; any subsequent adjuvant radiation will be delivered at the discretion of the treating physician
Biopsy does not meet inclusion criteria
PHASE II: For participation in the imaging research studies, patients must meet the additional following criteria:
-\n\n        All patients must meet the following inclusion criteria:\n\n          . Metastatic or unresectable locally advanced NSCLC\n\n          . Evidence of a tumor with one or more EGFR mutations excluding exon  insertion\n\n          . Biopsy of either primary or metastatic tumor tissue within  days of dosing\n\n          . Eastern Cooperative Oncology Group (ECOG) performance status of  to \n\n          . Minimum age of  years\n\n          . Adequate hematological and biological function\n\n          . Written consent on an IRB/IEC-approved Informed Consent Form (ICF) prior to any\n             study-specific evaluation\n\n        Phase  Cohorts must also meet the following inclusion criteria:
NSCLC patients must meet criteria for MET and/or Axl expression or,
HNSCC patients must meet criteria for MET and/or Axl expression or,
Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture and biopsy negative in suspected radiographic lesions and meet other organ function criteria.
Patients must meet pre-entry requirements
The patient must meet one of the following (a) or (b) or (c):
The patient must meet one of the following (a) or (b) or (c):
Must meet all inclusion criteria defined in main study and in addition the following criteria must be met:
Serum LDH >  x ULN (Upper limit of normal); . For Cohort B subject must be ?  years of age at the time of signing the informed consent form (ICF) and transplant non-eligible (TNE); excluding the subjects who meet the Cohort A criteria . For Cohort C subject must be after first autologous stem cell transplantation (ASCT) for NDMM and meet the following criteria:
Part  Dose Escalation subjects must meet  of the following criteria:
Part  Dose Expansion subjects must meet  of the following criteria:
Patients who do not meet parent protocol criteria to continue study treatment.
Blood counts performed within  days prior to randomization must meet the following criteria:
Patients with prior radiation therapy are eligible if they meet the following criteria:
Subjects in the combination therapy cohorts must meet the above inclusion criteria and be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator.
Subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator.
For Phase , subjects with the following tumor types who meet protocol-defined criteria: advanced or metastatic NSCLC, melanoma, urothelial carcinoma, SCCHN, SCLC, and CRC.
Successful T cell test expansion (to be performed as part of inclusion criteria until  subjects meet all enrollment criteria)
Patients are permitted to washout current drug therapy to meet these entry criteria if they have a known diagnosis of Cushing's disease.
Note: Patients who fail to meet the inclusion/exclusion criteria should not, under any circumstances, be initiated on study treatment; there can be no exceptions to this rule, although during protocol development, discussions about certain criteria are possible and may be amended, depending on new data and specific study requirements; where patients that do not meet the inclusion criteria are incorrectly started on treatment, or where patients subsequently fail to meet the study criteria post initiation, the investigator should inform the AZD team immediately; the AZD team is to ensure all such contacts are appropriately documented
Patients with cancer are eligible provided they meet the specifications
Subjects must meet the following criteria:
Must meet one of the following two criteria:
Baseline hematologic studies and chemistry profiles must meet the following criteria:
Patients must meet all of the following criteria to be enrolled in the study:
Bilateral breast cancers that individually meet eligibility criteria are allowed
Patients failing to meet the inclusion criteria
Failure to meet any of the criteria set forth in inclusion
Lysate must meet release criteria
Subject for whom tumor lysate does not meet release criteria
Platelet count ? ,/mm Arms B, C, and D must meet the following criteria:
DIAGNOSTIC CRITERIA
CRITERIA FOR RANDOMIZATION\r\n* Participants must meet the following criteria to qualify for HD-ADE versus Clo/AraC randomization; participants who do not meet these criteria may still be enrolled, but will be treated on HD-ADE arm and will NOT be randomized
LOW RISK MEDULLOBLASTOMA (patients must meet all of the following criteria):
Patients less than  years of age at diagnosis must meet one of the two following criteria:
CRITERIA FOR ALL SUBJECTS:
DONOR: Failure to meet FHCRC criteria for stem cell donation
DONOR: Failure to meet institutional criteria for donation as described in the Standard Practice Guidelines
Patients must meet diagnostic criteria for NF including presence of bilateral VS ( patients) or idiopathic VS without evidence of genetic syndrome ( patients)
Patients must meet laboratory, and bone marrow histological criteria for primary myelofibrosis as defined by World Health Organization (WHO) diagnostic criteria as follows: WHO diagnostic criteria for PMF Proposed Criteria for PMF Major Criteria
Subjects in Cohort  of Arm C must meet the following criteria:
Participant must meet at least one of the following criteria in the judgment of the investigator or sub-investigator:
ALC ? /?l (Note: Patients with AML are not required to meet these hematologic criteria).
Cardiac Exclusion Criteria: Patients will be excluded if these meet any of the following:
Prior therapy must meet all of the following criteria:
Patients who do not meet the above inclusion criteria will not receive leukapheresis
Subjects who fail to meet the above criteria
Meet all eligibility criteria with the exception of:\r\n* Prior therapy with trametinib will be permitted\r\n* All laboratory parameters must be met as outlined except for ALT and total bilirubin, which must meet criteria for continued therapy\r\n* Patients who are eligible for cross-over will not need to undergo another ophthalmologic examination
All of the criteria listed above
Specifically, subjects must meet one or more of the following criteria:
Patients must meet one or more of the following indications for treatment:
Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below):
Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria above.
Patients who have an active or uncontrolled infection are excluded. Patients on prolonged antifungal therapy are still eligible if they are culture and biopsy negative in suspected radiographic lesions and meet other organ function criteria.
Subjects must meet general eligibility criteria.
Patients eligible for HSCT at the time of screening. However, patients who meet one or both of the following criteria may be eligible for study participation:
Meet at least one of the criteria below:
Patients must meet criteria for acute lung injury
Failure to meet any of the criteria set forth in Section ..
Must meet all inclusion and exclusion criteria
Patients previously treated with carfilzomib are eligible as long as they meet the following criteria:
Patients must meet pre-entry requirements
Usability Test interview participants must meet criteria above and may also include patients who have undergone one or more cycles of treatment
Patients disease status should meet criteria as outlined by institutional master protocol
Patients on full dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:
If they are not patients of Massey Cancer Center or do not meet the inclusion criteria listed above
Meet all screening requirements
Meet screening criteria
Children who do not meet the above criteria
Meet screening criteria
For Aim , all patients must meet the following criteria:
Meet all inclusion criteria above
Patients are to be excluded from randomization for Aim  of this study if they meet any of the following criteria:
Subjects with bilateral disease are eligible if they meet other eligibility criteria
Patients who will be enrolled on the observational arm should meet the nd, rd, and th inclusion criteria only
Patients who will be enrolled on the observational arm should not meet the rd and th exclusion criteria only
Patients may undergo electrolyte repletion therapy to meet eligibility requirements
meet diagnostic criteria for chronic insomnia (i.e., lasting for at least one month)
DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local criteria for stem cell donation
If women have had a hysterectomy and still have their ovaries, they must meet the FSH criteria described above
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: NOTE: patient does not need to meet all subprotocol criteria at time of enrollment onto the APEC screening protocol, but will need to meet all criteria prior to enrollment on any assigned treatment subprotocol; patients must be enrolled onto a subprotocol within  weeks ( days) of treatment assignment
Participants must meet any one of the following  criteria:
Any lab results that do not meet inclusion criteria after the Screen  blood tests
IF PROTOCOL  SERVES AS AN ADJUNCT PROTOCOL, THE PATIENTS ONLY NEEDS TO MEET INCLUSION CRITERIA  THROUGH A
IF PROTOCOL  SERVES AS AN ADJUNCT PROTOCOL, THE PATIENT ONLY NEEDS TO MEET EXCLUSION CRITERIA  THROUGH 
DONOR: Failure to meet local criteria for stem cell donation
Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet all of the inclusion and none of the exclusion criteria
Use of antidepressants is permitted if dose has been the same for at least  weeks prior to study entry if patient still DOES NOT meet exclusion criteria #
Patients failing to meet the inclusion criteria
Subjects who do not meet the above mentioned inclusion criteria
Patients with a locoregional tumor recurrence following surgery will be eligible provided they meet other eligibility criteria
Does not meet above criteria of suspicious PSA elevation
Biopsy does not meet inclusion criteria
All subjects enrolled into either Part  or Part  must meet all of the following inclusion criteria to be eligible:
Does not meet histologic criteria
The participant must meet the following criteria relevant to their specific diagnosis:
Must meet at least  of the following  criteria for progressive metastatic disease, according to Prostate Cancer Working Group  (PCWG) criteria:
Will include all prospective trial participants in this study that come from Twitter in response of our SM recruitment interventions, provided they meet the specific trial's eligibility criteria
Persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
Admission or evidence of illicit drug use, drug abuse, or alcohol abuse. Entry Criteria for Continuation to Optional Part B: After completing Part A of the study, participants may choose to enter the optional Part B of the study. To be eligible for the optional Part B, participants must have completed Part A and be reassessed to determine if they meet the entry criteria for optional Part B. Only participants who meet the following criteria may enter into Part B:
Participants with a history of CNS metastases are eligible provided they are stable and meet the criteria details in the protocol.
Patients eligible for this companion sample collection protocol must not meet any of the exclusion criteria in the CLEEA study, in addition to the following: